|Bid||18.00 x 400|
|Ask||25.00 x 200|
|Day's Range||23.30 - 25.00|
|52 Week Range||16.75 - 30.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.67|
TUCSON, Ariz., March 23, 2018-- Accelerate Diagnostics, Inc. today announced the pricing of $150.0 million aggregate principal amount of 2.50% convertible senior notes due 2023 in a private placement to ...
TUCSON, Ariz., March 22, 2018-- Accelerate Diagnostics, Inc. today announced its intention to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of convertible ...
NEW YORK, March 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Accelerate Diagnostics Inc (NASDAQ:AXDX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Insider buying can be an encouraging signal for potential investors. Several health care companies saw notable insider buying this past week. Insiders included a company founder and a renowned former CEO. ...
The Tucson, Arizona-based company said it had a loss of 27 cents per share. The maker of systems that diagnose drug-resistant infections posted revenue of $2.1 million in the period. For the year, the ...
TUCSON, Ariz., Feb. 15, 2018-- Accelerate Diagnostics, Inc. today announced preliminary full-year 2017 financial results including the quarter ending December 31, 2017. The company reported revenue for ...
Short interest is moderately high for AXDX with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding AXDX totaled $457 million.
TUCSON, Ariz., Feb. 08, 2018-- Accelerate Diagnostics, Inc. will host a conference call on Thursday, February 15, 2018 to review its fourth quarter and full-year financial results for 2017.. President ...
How Is Accelerate Diagnostics Positioned at the Start of 2018? In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock. As a result of the offering, the cash position of the company increased to $121.3 million at the end of 3Q17 as compared with $77.8 million at the end of 3Q16.
How Is Accelerate Diagnostics Positioned at the Start of 2018? The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17. For fiscal 2017, Accelerate Diagnostics is expected to report revenues of $5 million, while peers Becton Dickinson (BDX), Bruker (BRKR), and Thermo Fisher Scientific (TMO) are expected to report revenues of $12 billion, $1.7 billion, and $20.5 billion, respectively.
How Is Accelerate Diagnostics Positioned at the Start of 2018? Accelerate Diagnostics’ (AXDX) Pheno System utilizes genotypic and phenotypic technology to identify infectious pathogens and perform antibiotic susceptibility tests (or AST), which determine if live bacterial or fungal cells are resistant or susceptible to a particular antimicrobial agent. The kit includes 140 assays for identification and susceptibility testing.
Tuscon-based Accelerate Diagnostics (AXDX) is a diagnostics company focused on developing solutions and tools to provide rapid diagnostic results. While results from traditional culture-based tests usually take two to three days, Accelerate’s technology platform is built to deliver substantially faster and more accurate testing of infectious pathogens. The platform is intended to rapidly diagnose infectious pathogens.
Accelerate Diagnostics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 71 to 83.
TUCSON, Ariz., Jan. 10, 2018-- Accelerate Diagnostics, Inc. announced today its declaration of conformity to the European In Vitro Diagnostic Directive 98/ 79/ EC and CE mark of its latest assay for the ...
Short interest is high for AXDX with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting AXDX. Over the last one-month, outflows of investor capital in ETFs holding AXDX totaled $4.56 billion.
NEW YORK, Jan. 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ConnectOne ...
TUCSON, Ariz., Jan. 04, 2018-- Accelerate Diagnostics, Inc. announced today that Lawrence Mehren, President and Chief Executive Officer is scheduled to speak at the 36th Annual J.P. Morgan Healthcare Conference ...
Accelerate Diagnostics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.
Accelerate Diagnostics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 75 to 82.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Accelerate Diagnostics, Inc. Here are 5 ETFs with the largest exposure to AXDX-US. Comparing the performance and risk of Accelerate Diagnostics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)